Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company aiming to solve patients’ problems by advancing current standards of care through simplifying complex delivery methods. Aquestive is developing orally administered products to provide novel alternatives to invasive and inconvenient standard of care therapies. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.
We are focused problem solvers who work to empower patients and their caregivers. Our team hails from a variety of backgrounds and disciplines, and has created a collaborative culture where different viewpoints are valued and challenging the status quo is the norm.
We’re fortunate to have experienced industry leaders on our active Board of Directors.
Our advisory board consists of world-renowned, experienced physicians who share our goal of simplifying complex treatment conditions to improve the patient experience in allergy.